GlassScriptPhysician profile
Raymond R Holt
NPI 1538183884
$9,436.39
in general payments reported to CMS, 2019-2025
44 companies · $2,029 in 2025
The $2,029 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $986 · 2020: $906 · 2021: $1,055 · 2022: $1,180 · 2023: $1,385 · 2024: $1,895 · 2025: $2,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,309.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $877.89 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $821.41 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $711.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $642.69 | 2021-2025 | |
| Pfizer INC. | $629.98 | 2019-2025 | |
| Glaxosmithkline, LLC. | $600.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $490.81 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $447.19 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $431.29 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $403.00 | 2019-2023 | |
| Abbott Laboratories | $395.17 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Lilly USA, LLC | $371.53 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Xeris Pharmaceuticals, INC. | $327.82 | 2022-2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $320.16 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $274.12 | 2023-2025 | Cologuard Collection Kit |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $217.32 | 2021-2025 | |
| Dexcom, INC. | $214.30 | 2022-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Astellas Pharma US INC | $213.36 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $111.87 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $100.74 | 2020-2024 | Gardasil 9, Gardasil, Capvaxive |
| Sumitomo Pharma America, INC. | $81.06 | 2023-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $69.87 | 2019-2022 | |
| Allergan, INC. | $68.09 | 2019-2020 | |
| Nevro Corp. | $58.29 | 2023 | Senza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.76 | 2024-2025 | Caplyta |
| Intra-Sana Laboratories | $50.00 | 2024 | Reltone 400 Mg, Reltone 200 Mg |
| Boston Scientific Corporation | $45.96 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Antares Pharma, INC. | $45.22 | 2022 | |
| Esperion Therapeutics, INC. | $40.44 | 2021-2023 | Nexletol |
| Inari Medical, INC. | $37.48 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Shield Therapeutics INC | $34.02 | 2024 | |
| Mylan Specialty L.P. | $30.80 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $29.46 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $27.93 | 2021 | |
| Daiichi Sankyo INC. | $26.71 | 2024 | Injectafer |
| Scilex Pharmaceuticals INC. | $19.72 | 2023 | Ztlido |
| Biohaven Pharmaceutical Holding Company LTD. | $18.07 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.25 | 2024 | Jardiance |
| Arbor Pharmaceuticals, INC. | $16.47 | 2021 | |
| Hologic Sales and Service, LLC | $16.21 | 2023 | Aptima, Thinprep 2000 Processor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.92 | 2022 | |
| Medtronic Minimed, INC. | $12.50 | 2019 | |
| Eisai INC. | $11.29 | 2021 | |
| Shire North American Group INC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.